Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896857 | 0.97 | BTK (0.40) | BTKDRD2DRD4DRD3JAK2 | |
| SCHEMBL9896856 | 0.97 | BTK (0.40) | BTKDRD2DRD4DRD3JAK2 | |
| SCHEMBL9896860 | 0.97 | BTK (0.40) | BTKDRD2DRD4DRD3JAK2 | |
| SCHEMBL9943127 | 0.87 | BTK (0.50) | BTKDRD2JAK2JAK1 | |
| SCHEMBL9900265 | 0.86 | BTK (0.42) | BTKJAK3 | |
| SCHEMBL9900273 | 0.86 | BTK (0.42) | BTKJAK3 | |
| SCHEMBL9900267 | 0.86 | BTK (0.42) | BTKJAK3 | |
| SCHEMBL9898541 | 0.84 | BTK (0.47) | BTKJAK2JAK1JAK3 | |
| SCHEMBL9928287 | 0.80 | CHEK1 (0.40) | JAK2JAK1JAK3 | |
| SCHEMBL9943114 | 0.77 | BTK (0.36) | BTKDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | BTK 50/4885DRD2 870/4885DRD4 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.